Invetx, a Boston-based innovator in protein-based therapies for animal health has raised $60.5 million in Series B financing.
F-Prime Capital, Novo Holdings, GV, GV (formerly Google Ventures), and Eight Roads led the round. Existing investors Anterra Capital, Casdin Capital, and Tekla Capital Management, LLC participated in the round.
The company plans to use these funds to expand its monoclonal anti (mAb) product pipeline and seek market approvals for therapeutics against chronic and serious diseases in both dogs and cats.
Invetx is headed by Juergen H. Horn, PhD, chief executive. This platform enables Invetx to develop fully species-specific and optimized products and extend their lives. Invetx can create differentiated antibodies for a variety of serious and chronic conditions in animals by using validated biotechnologies, which are optimized for use in veterinary medicine. Invetx is developing a wide range of biotherapeutics across a variety of therapeutic areas. It expects to have multiple candidates in development and product approvals possible as soon as 2025. The company also has a partnership with Boehringer Ingelheim for discovery, development and commercialization to develop new programs. Invetx has expanded its collaborations to Twist Bioscience, AbCellera and Wuxi Biologics.